Clinical Experience With Zonisamide Monotherapy and Adjunctive Therapy in Children With Epilepsy at a Tertiary Care Referral Center

Abstract

We evaluated our clinical experience with zonisamide, a broad-spectrum antiepileptic drug, in a group of children with predominantly medically refractory epilepsy. A retrospective chart review was conducted on patients at our tertiary referral center following Institutional Review Board approval. Observers documented reports of seizure frequency, and seizure types were identified either clinically or by prior video-electroencephalography monitoring. We identified 68 patients (age range 1.9—18.1 years [median 6.9 years]; male to female ratio 1.3:1) treated with zonisamide for 0.7 to 28.9 months; at the last visit, 22% and 78% were on monotherapy and adjunctive therapy, respectively. The median duration of treatment and maintenance dose at the end of the follow-up were 11.2 months and 8.0 mg/kg/day, respectively. Seizure types included generalized (primary generalized tonic-clonic, myoclonic, tonic, atonic, absence) and partial (simple, complex, and secondarily generalized tonic-clonic seizures); 10 (15%) patients had both partial and generalized seizures. Sixteen (25.8%) patients were seizure free, although five of them were already in remission prior to starting zonisamide. Thirteen (21.0%) patients had a ≥ 50% seizure reduction, 10 (16.1%) patients had a < 50% seizure reduction, 14 (22.6%) had no improvement in baseline seizures, and 9 (14.5%) reported having increased seizures. The latter were mostly associated with dosage alterations in concomitant antiepileptic drugs. Common side effects were central nervous system related, including behavioral or psychiatric (23.5%), cognitive dysfunction (12.0%), and sedation (10.3%). Eleven (16.2%) patients ultimately discontinued zonisamide, but only five were strictly due to side effects. Zonisamide is clinically effective against multiple seizure types in a significant proportion of children with epilepsy across a broad age range. Drug discontinuation as a result of side effects is uncommon. (J Child Neurol 2005;20:212—219).

Get full access to this article

View all access options for this article.

References

Peters DH , Sorkin EM : Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993;45:760—787.

Rock DM , Macdonald RL , Taylor CP : Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989;3:138—143.

Schauf CL : Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185—188.

Suzuki S. , Kawakami K. , Nishimura S. , et al: Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21—27.

Mimaki T. , Suzuki Y. , Tagawa T. , et al: Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 1990;39:13—17.

Masuda Y. , Noguchi H. , Karasawa T. : Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects. Arzneimittelforschung 1994;44:267—269.

Ito T. , Hori M. , Masuda Y. , et al: 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile. Arzneimittelforschung 1980;30:603—609.

Kamei C. , Oka M. , Masuda Y. , et al: Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats. Arch Int Pharmacodyn Ther 1981;249:164—176.

Takano K. , Tanaka T. , Fujita T. , et al: Zonisamide: Electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats. Epilepsia 1995;36:644—648.

10.

Masuda Y. , Utsui Y. , Shiraishi Y. , et al: Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 1979;20:623—633.

11.

Masuda Y. , Karasawa T. , Shiraishi Y. , et al: 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforschung 1980;30:477—483.

12.

Oommen KJ , Mathews S. : Zonisamide: A new antiepileptic drug. Clin Neuropharmacol 1999;22:192—200.

13.

Schmidt D. , Jacob R. , Loiseau P. , et al: Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res 1993;15:67—73.

14.

Faught E. , Ayala R. , Montouris GG , Leppik IE : Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774—1779.

15.

Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures . Epilepsia 1981;22:489—501.

16.

Kochak GM , Page JG , Buchanan RA , et al: Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998; 38:166—171.

17.

Wilensky AJ , Friel PN , Ojemann LM , et al: Zonisamide in epilepsy: A pilot study . Epilepsia 1985;26:212—220.

18.

Minami T. , Ieiri I. , Ohtsubo K. , et al: Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia 1994;35:1023—1025.

19.

Tasaki K. , Minami T. , Ieiri I. , et al: Drug interactions of zonisamide with phenytoin and sodium valproate: Serum concentrations and protein binding. Brain Dev 1995;17:182—185.

20.

Ojemann LM , Shastri RA , Wilensky AJ , et al: Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986;8:293—296.

21.

Glauser TA , Pellock JM : Zonisamide in pediatric epilepsy: Review of the Japanese experience. J Child Neurol 2002;17:87—96.

22.

Fukushima K. , Yagi K. , Seino M. : Phase II clinical trial of a new antiepileptic drug, zonisamide (ZNA) in pediatric epilepsy patients. Jpn J Pediatr 1987;40:3389—3397.

23.

Takahashi I. , Yamamoto N. , Furune S. , et al: Efficacy of zonisamide for intractable epilepsy in childhood. J Jpn Epilepsy Soc 1987; 5:100—105.

24.

Sakamoto K. , Kurokawa T. , Tomita S. , et al: Effects of zonisamide in children with epilepsy. Curr Ther Res 1988;43:378—383.

25.

Tagawa T. , Mimaki T. , Shuto H. , et al: Treatment of pediatric epilepsies with zonisamide (AD-810). J Pediatr Pract 1988;51:539—543.

26.

Oguni H. , Hayakawa T. , Fukuyama Y. : Clinical trial of zonisamide, a new antiepileptic drug in cases of refractory childhood epilepsy. J Jpn Epilepsy Soc 1989 ;7:43—50.

27.

Shuto H. , Sugimoto T. , Yasuhara A. , et al: Efficacy of zonisamide in children with refractory partial seizures . Curr Ther Res 1989; 45:1031—1036.

28.

Motte J. , Trevathan E. , Arvidsson JF , et al: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807—1812.

29.

Sachdeo RC , Glauser TA , Ritter F. , et al: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:1882—1887.

30.

Suzuki Y. , Nagai T. , Ono J. , et al: Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38:1035—1038.

31.

Yanai S. , Hanai T. , Narazaki O. : Treatment of infantile spasms with zonisamide. Brain Dev 1999;21:157—161.

32.

Kishi T. , Nejihashi Y. , Kajiyama M. , Ueda K. : Successful zonisamide treatment for infants with hypsarrhythmia. Pediatr Neurol 2000;23:274—277.

33.

Suzuki Y. : Zonisamide in West syndrome. Brain Dev 2001 ; 23:658—661.

34.

Ohno M. , Shimotsuji Y. , Abe J. : Zonisamide treatment of early infantile epileptic encephalopathy. Pediatr Neurol 2000;23:341—344.

35.

Kanazawa, O. : Refractory grand mal seizures with onset during infancy including severe myoclonic epilepsy in infancy. Brain Dev 2001;23:749—756.

36.

Henry TR , Leppik IE , Gumnit RJ , Jacobs M. : Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38:928—931.

37.

Kyllerman M. , Ben-Menachem E. : Zonisamide for progressive myoclonus epilepsy: Long-term observations in seven patients. Epilepsy Res 1998;29:109—114.

38.

Yoshimura I. , Kaneko S. , Yoshimura N. , Murakami T. : Long-term observations of two siblings with Lafora disease treated with zonisamide . Epilepsy Res 2001;46:283—287.

39.

Kumagai N. , Seki T. , Yamawaki H. , et al: Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatry Neurol 1991;45: 357—359.

40.

Hayakawa T. , Nejihashi Y. , Kishi T. , et al: Serum zonisamide concentration in fresh cases of childhood epilepsy following zonisamide monotherapy. J Jpn Epilepsy Soc 1994;12:249—254.

41.

Hosoda N. , Miura H. , Takanashi S. , et al: Once-daily dose of zonisamide monotherapy in the control of parital seizures in children with cryptogenic localization-related epilepsies: Clinical effects and their pharmacokinetic basis. Jpn J Psychiatry Neurol 1994;48:335—337.

42.

Oguni H. , Hayashi K. , Fukuyama Y. , et al: Phase III clinical study of the new antiepileptic drug AD-810 (zonisamide) in patients with childhood epilepsy. Jpn J Pediatr 1988;41:439—450.

43.

Hirai K. , Kimiya S. , Tabata K. , et al: Selective mutism and obsessive compulsive disorders associated with zonisamide. Seizure 2002;11:468—470.

44.

Kimura S. : Zonisamide-induced behavior disorder in two children. Epilepsia 1994;35:403—405.

45.

Miyamoto T. , Kohsaka M. , Koyama T. : Psychotic episodes during zonisamide treatment . Seizure 2000;9:65—70.

46.

Charles CL , Stoesz L. , Tollefson G. : Zonisamide-induced mania. Psychosomatics 1990 ;31:214—217.

47.

Akman CI , Goodkin HP , Rogers DP , Riviello JJ Jr : Visual hallucinations associated with zonisamide. Pharmacotherapy 2003; 23:93—96.